Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolin C Hack

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Geburtshilfe Und Frauenheilkunde|February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Geburtshilfe Und Frauenheilkunde|April 19, 2021
Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020)Stefanie Burghaus, Sebastian D Schäfer, Matthias W Beckmann, et al.
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and TherapyMatthias W Beckmann, Frederik A Stübs, Martin C Koch, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Geburtshilfe Und Frauenheilkunde|February 12, 2024
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Geburtshilfe Und Frauenheilkunde|April 19, 2021
Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020)Stefanie Burghaus, Sebastian D Schäfer, Matthias W Beckmann, et al.
International Journal of Cancer|July 11, 2025
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trialMilena Beierlein, Lothar Häberle, Naiba Nabieva, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|May 1, 2024
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace StudyCarolin C Hack, Nicolai Maass, Bahriye Aktas, et al.
Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Geburtshilfe Und Frauenheilkunde|February 16, 2022
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and TherapyMatthias W Beckmann, Frederik A Stübs, Martin C Koch, et al.
Pageof 10